Transjugular intrahepatic portosystemic shunt for the treatment of portal hypertension due to idiopathic myelofibrosis

Internal Medicine

Volumn 46, Issue 4, 2007, Pages 187-190

  Doki, Noriko ^a   Irisawa, Hiroyuki ^a   Takada, Satoru ^a   Sakura, Tohru ^a   Miyawaki, Shuichi ^a  

^a SAISEIKAI MAEBASHI HOSPITAL   (Japan)

Author keywords

Idiopathic myelofibrosis (IMF); Portal hypertension; Sinusoidal fibrosis; Transjugular intrahepatic portosystemic shunt (TIPS)

Indexed keywords

DIURETIC AGENT;

ADULT; ANEMIA; ARTICLE; ASCITES; AUTOPSY; BLOOD TRANSFUSION; BONE MARROW BIOPSY; CASE REPORT; CLINICAL FEATURE; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG INFUSION; ESOPHAGUS VARICES; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IDIOPATHIC DISEASE; LABORATORY TEST; LIVER FAILURE; LIVER FUNCTION TEST; MALE; MONOTHERAPY; MYELOFIBROSIS; PATIENT ASSESSMENT; PORTAL HYPERTENSION; PORTOSYSTEMIC ANASTOMOSIS; SCLEROTHERAPY; TREATMENT CONTRAINDICATION; WAIST CIRCUMFERENCE;

DISEASE PROGRESSION; FATAL OUTCOME; FIBROSIS; HEPATOMEGALY; HUMANS; HYPERTENSION, PORTAL; MALE; MIDDLE AGED; MYELOFIBROSIS; PORTASYSTEMIC SHUNT, TRANSJUGULAR INTRAHEPATIC; RISK ASSESSMENT;

EID: 33847017683     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.46.1768     Document Type: Article

References (15)

1. Lukie BE, Card RT. Portal hypertension complicating myelofibrosis: reversal following splenectomy. Can Med Assoc J 117: 771-772, 1977.
2. Visani G, Finelli C, Castelli U, et al. Myelofibrosis with myeloid metaplasia: clinical and haematological parameters predicting survival in a series of 133 patients. Br J Haematol 75: 4-9, 1990.
3. Roux D, Merlio JP, Quinton A, Lamouliatte H, Balabaud C, Bioulac-Sage P. Agnogenic myeloid metaplasia, portal hypertension, and sinusoidal abnormalities. Gastroenterology 92: 1067-1072, 1987.
4. Tsao MS. Hepatic sinusoidal fibrosis in agnogenic myeloid metaplasia. Am J Clin Pathol 91: 302-305, 1989.
5. Wanless IR, Peterson P, Das A, Boitnott JK, Moore GW, Bernier V. Hepatic vascular disease and portal hypertension in polycythemia vera and agnogenic myeloid metaplasia: A clinicopathological study of 145 patients examined at autopsy. Hepatology 12: 1166-1174, 1990.
6. Wiest R, Strauch U, Wagner H, et al. A patient with myelofibrosis complicated by refractory ascites and portal hypertension: to tips or not to tips? A case report with discussion of the mechanism of ascites formation. Scand J Gastroenterol 39: 389-394, 2004.
7. Kumar V, Cotran RS, Robbins SL. Basic pathology 7th ed. W.B. Saunders, Philadelphia, 2003: 290-298.
8. Assoian RK, Komoriya A, Myers CA, Miller DM, Sporn MB. Transforming growth factor-beta in human platelets. J Biol Chem 258: 7155-7160, 1983.
9. Bioulac-Sage P, Roux D, Quinton A, Lamouliatte H, Balabaud C. Ultrastructure of sinusoids in patients with agnogenic myeloid. metaplasia. I Submicrosc Cytol 18: 815-821, 1986.
10. Rossle M, Siegerstetter V, Huber M, Ochs A. The first decade of the transjugular intrahepatic portosystemic shunt (TIPS): state of the art. Liver 18: 73-89, 1998.
11. Sanyal AJ. The use and misuse of transjugular intrahepatic portasystemic shunts. Curr Gastroenterol Rep 2: 61-71, 2000.
12. Angermayr B, Cejna M, Schoder M, et al. Transjugular intrahepatic portosystemic shunt for treatment of portal hyprtension due to extramedullary hematopoiesis in idiopathic myelofibrosis. Blood 99: 4246-4247, 2002.
13. Belohlavek J, Schwarz J, Jirasek A, Krajina A, Polak F, Hruby M. Idiopathic myelofibrosis complicated by portal hypertension treated with a transjugular intrahepatic portosystemic shunt (TIPS). Wien Klin Wochenschr 113: 208-211, 2001.
14. Kobayashi S, Matsui O, Yoshikawa J, et al. Prevention of hepatic infarction as acute-phase complication of TIPS by temporary balloon occlusion in a patient with primary myelofibrosis. Radiat Med 22: 432-436, 2004.
15. Deeg HJ, Gooley TA, Flowers ME, et al. Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Blood 102: 3912-3918, 2003.